Editorial · 1 Dec 2025
Research articlePublished 8 Mar 2023
A Randomized Open Label Parallel Clinical Study to Evaluate the Safety and Efficacy of Clevira Tablets against Mumps, HPV and Herpes zoster
1apex laboratories private limited R&D centre, B/59, SIPCOT Industrial Park, Irungattukottai, Sriperumbudur Taluk, Kancheepuram District- 602117, India; 2SpinoS Life Science and Research Private limited, Krishna Madura Vanam, VellakinarPirivu, Thudiyalur, Coimbatore-29, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: To compare the clinical efficacy of Clevira tablets in Human adult patients, with Mumps, HPV and Herpes zoster. Methods: An Open Label, Balanced, Randomized, Multi-Dose, Two-Treatment, Parallel, Comparative Phase III Clinical trial to determine the Safety and efficacy of Clevira Tablets. 20 Patients were enrolled for two types of treatments received. Treatment 1-Clevira Tablets for Mumps/HPV (n=10) and Treatment 2- Clevira Tablets for Herpes Zoster virus(n=10). Enrolment was based upon the diagnosis of Haematology, Biochemistry, Serology, RT-PCR and Chest X-Ray and inclusion and none of the exclusion criteria and included in the study. Results: All the patients demonstrated safety measures with respect to Blood pressure and Pulse rate. Also, statistically significant (p < 0.0001) improvement showed in temperature from baseline for Treatment 1- (101.89 ± 1.14) and at the end of the study period (97.84 ± 0.83), improvement showed in temperature from baseline for Treatment 2- (101.82 ± 1.15) and at the end of the study period (97.74 ± 0.88). Conclusion: The study demonstrated an expedited clinical cure with normal vital signs & haematological results which validated that Tablet Clevira is safe and efficacious in patients with Mumps/HPV and Herpes zoster virus. The data’s further entrusted that Clevira can be used in infected patients with Mumps/HPV and Herpes zoster, and relieve the signs and symptoms, with a rapid recovery, without any adverse side effects.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Infectious Diseases & Practice.
Editorial · 1 Dec 2025
Evolving Clinical Mycology: Diagnosis, Resistance, and Novel Therapies
Opinion · 1 Dec 2025
Point-of-Care Testing: Revolutionizing Infectious Disease Diagnostics
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Infectious Diseases & Practice
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Anoop Austin”
- BylineArticles whose byline prints “Abiraamasundari”
- BylineArticles whose byline prints “Esekia Raja Selvan D”